Tough Times Ahead For Towa As Japanese Generics Giant Slashes 2023 Predictions
Net Profits In Q2 Down Over 70%
Towa has made substantial cuts to its 2023 financial guidance as the difficult conditions of the Japanese generics market begin to take their toll.
You may also be interested in...
Towa Profits Take 87% Nosedive In Face Of Increased Costs
Japanese generics firm Towa has seen its profits slashed as increased expenses stemming from its acquisition of Sunsho Pharmaceutical decimated its bottom line in Q3.
Sawai’s Japan Core Profit Tumbles 39% As Upsher-Smith Continues Revival
Sawai’s Q1 momentum spread into its overall first half financial results, with setbacks and risks in its dominant Japanese business and greener shoots for its formerly spluttering Upsher-Smith operation in the US.
Fear of Unpredictability: Industry Criticises Japan’s Frequent Pricing Rule Changes
While Japan enters annual drug price revisions with frequent regulation changes, several major corporate players in the country warn again that government policies mean that the country is at risk of “losing attractiveness.”